Clinical trial
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies
NCT02329847 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 11, 2015
- Completion date
- February 9, 2022
- Enrollment
- 144 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.